Faculty of 1000 evaluation for A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium.

Author(s):  
Burton Eisenberg
Sign in / Sign up

Export Citation Format

Share Document